S&P 500   3,172.77 (+1.42%)
DOW   27,461.47 (+1.40%)
QQQ   219.75 (+2.03%)
AAPL   296.38 (+2.88%)
FB   200.05 (+1.67%)
MSFT   172.61 (+2.70%)
GOOGL   1,409.22 (+1.65%)
AMZN   2,011.00 (+1.94%)
CGC   20.19 (+2.91%)
NVDA   274.05 (+4.58%)
BABA   212.07 (+3.14%)
MU   53.91 (+3.47%)
GE   11.46 (+1.24%)
TSLA   794.02 (-0.74%)
AMD   48.85 (+2.69%)
T   37.54 (+0.48%)
ACB   1.52 (+0.66%)
F   7.43 (+2.77%)
NFLX   376.27 (+4.49%)
PRI   123.79 (+1.95%)
BAC   31.45 (+1.19%)
DIS   127.41 (-0.61%)
S&P 500   3,172.77 (+1.42%)
DOW   27,461.47 (+1.40%)
QQQ   219.75 (+2.03%)
AAPL   296.38 (+2.88%)
FB   200.05 (+1.67%)
MSFT   172.61 (+2.70%)
GOOGL   1,409.22 (+1.65%)
AMZN   2,011.00 (+1.94%)
CGC   20.19 (+2.91%)
NVDA   274.05 (+4.58%)
BABA   212.07 (+3.14%)
MU   53.91 (+3.47%)
GE   11.46 (+1.24%)
TSLA   794.02 (-0.74%)
AMD   48.85 (+2.69%)
T   37.54 (+0.48%)
ACB   1.52 (+0.66%)
F   7.43 (+2.77%)
NFLX   376.27 (+4.49%)
PRI   123.79 (+1.95%)
BAC   31.45 (+1.19%)
DIS   127.41 (-0.61%)
S&P 500   3,172.77 (+1.42%)
DOW   27,461.47 (+1.40%)
QQQ   219.75 (+2.03%)
AAPL   296.38 (+2.88%)
FB   200.05 (+1.67%)
MSFT   172.61 (+2.70%)
GOOGL   1,409.22 (+1.65%)
AMZN   2,011.00 (+1.94%)
CGC   20.19 (+2.91%)
NVDA   274.05 (+4.58%)
BABA   212.07 (+3.14%)
MU   53.91 (+3.47%)
GE   11.46 (+1.24%)
TSLA   794.02 (-0.74%)
AMD   48.85 (+2.69%)
T   37.54 (+0.48%)
ACB   1.52 (+0.66%)
F   7.43 (+2.77%)
NFLX   376.27 (+4.49%)
PRI   123.79 (+1.95%)
BAC   31.45 (+1.19%)
DIS   127.41 (-0.61%)
S&P 500   3,172.77 (+1.42%)
DOW   27,461.47 (+1.40%)
QQQ   219.75 (+2.03%)
AAPL   296.38 (+2.88%)
FB   200.05 (+1.67%)
MSFT   172.61 (+2.70%)
GOOGL   1,409.22 (+1.65%)
AMZN   2,011.00 (+1.94%)
CGC   20.19 (+2.91%)
NVDA   274.05 (+4.58%)
BABA   212.07 (+3.14%)
MU   53.91 (+3.47%)
GE   11.46 (+1.24%)
TSLA   794.02 (-0.74%)
AMD   48.85 (+2.69%)
T   37.54 (+0.48%)
ACB   1.52 (+0.66%)
F   7.43 (+2.77%)
NFLX   376.27 (+4.49%)
PRI   123.79 (+1.95%)
BAC   31.45 (+1.19%)
DIS   127.41 (-0.61%)
Log in

NASDAQ:KZR - Kezar Life Sciences Stock Price, Forecast & News

$5.51
+0.01 (+0.18 %)
(As of 02/26/2020 10:45 AM ET)
Today's Range
$5.28
Now: $5.51
$5.58
50-Day Range
$2.77
MA: $3.92
$5.75
52-Week Range
$2.36
Now: $5.51
$22.33
Volume116,801 shs
Average Volume490,910 shs
Market Capitalization$194.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KZR
CUSIPN/A
CIKN/A
Phone650-822-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.69 per share

Profitability

Net Income$-23,170,000.00

Miscellaneous

Employees24
Market Cap$194.28 million
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive KZR News and Ratings via Email

Sign-up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.


Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences Inc (NASDAQ:KZR) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.03. View Kezar Life Sciences' Earnings History.

When is Kezar Life Sciences' next earnings date?

Kezar Life Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Kezar Life Sciences.

What price target have analysts set for KZR?

3 brokers have issued 12-month price targets for Kezar Life Sciences' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate Kezar Life Sciences' stock price to reach $15.00 in the next year. This suggests a possible upside of 172.2% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

What is the consensus analysts' recommendation for Kezar Life Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

Has Kezar Life Sciences been receiving favorable news coverage?

Headlines about KZR stock have trended somewhat positive on Wednesday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kezar Life Sciences earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the near term. View News Stories for Kezar Life Sciences.

Who are some of Kezar Life Sciences' key competitors?

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Opko Health (OPK), Aptinyx (APTX), Ovid Therapeutics (OVID), vTv Therapeutics (VTVT), Kadmon (KDMN), ADMA Biologics (ADMA), Blueprint Medicines (BPMC), Codexis (CDXS), Crispr Therapeutics (CRSP) and Exelixis (EXEL).

Who are Kezar Life Sciences' key executives?

Kezar Life Sciences' management team includes the folowing people:
  • Mr. John Fowler, Co-Founder, CEO & Director (Age 47)
  • Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 47)
  • Dr. Jack Taunton, Co-Founder
  • Mr. Marc L. Belsky, CFO & Sec. (Age 64)
  • Michael Wolfe, Director of Fin. & Operations

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Victory Capital Management Inc. (6.66%), Victory Capital Management Inc. (2.59%), State Street Corp (1.19%), Geode Capital Management LLC (0.37%) and Acadian Asset Management LLC (0.64%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides. View Institutional Ownership Trends for Kezar Life Sciences.

Which institutional investors are selling Kezar Life Sciences stock?

KZR stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, Alambic Investment Management L.P., Goldman Sachs Group Inc., Renaissance Technologies LLC and State Street Corp. View Insider Buying and Selling for Kezar Life Sciences.

Which institutional investors are buying Kezar Life Sciences stock?

KZR stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BVF Inc. IL, Acadian Asset Management LLC, FMR LLC, Victory Capital Management Inc., Private Advisors LLC, Bank of Montreal Can and Barclays PLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides. View Insider Buying and Selling for Kezar Life Sciences.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $5.51.

How big of a company is Kezar Life Sciences?

Kezar Life Sciences has a market capitalization of $194.28 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.View Additional Information About Kezar Life Sciences.

What is Kezar Life Sciences' official website?

The official website for Kezar Life Sciences is http://www.kezarlifesciences.com/.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]


MarketBeat Community Rating for Kezar Life Sciences (NASDAQ KZR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote "Outperform" if you believe KZR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel